Bal Pharma Peer Comparison

Bal Pharma Ltd. demonstrates moderate growth and reasonable valuation metrics compared to its peers in the Pharmaceuticals & Drugs sector. While it shows potential in profitability, there are stronger performers in terms of growth and returns on equity. Companies like Dr. Reddy's Laboratories and Cipla are leading in profitability, while Bal Pharma is relatively stable but lacks exceptional metrics. However, it remains a viable option for investors seeking value in a competitive landscape.

• • Bal Pharma shows a solid revenue growth of 11.51% YoY, but peers like Mankind Pharma lead with 18.12%.
• • The company's PE ratio at 18.10 positions it favorably compared to many peers, indicating potential value.
• • ROE of 11.19% is lower than top performers like Dr. Reddy's (21.76%), suggesting room for improvement in shareholder returns.

• • Dr. Reddy's Laboratories Ltd.: Highest ROE of 21.76% and strong growth metrics.
• • Cipla Ltd.: High profitability with an ROE of 16.63% and a decent growth rate.
• • Mankind Pharma Ltd.: Best revenue growth at 18.12% YoY, indicating strong market performance.